Business
NeuroSense to Host Investor Webinar on September 12, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts are invited to register for the webinar
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts are invited to register for the webinar event.\nCAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, announced today it will host an investor webinar conference on Tuesday, September 12, 2023 from 8:30 AM to 9:15 AM Eastern Time.\nNeuroSense's CEO, Alon Ben-Noon, VP of R&D, Dr. Shiran Zimri, Chief Medical Officer, Dr. Ferenc Tracik and VP of BD, Nedira Salzman, will present to investors and analysts, followed by a Q&A. The presentation will focus on NeuroSense's scientific advances, its Phase 2b amyotrophic lateral sclerosis (ALS) clinical trial design, endpoints, and progress, Alzheimer Disease (AD) Phase 2 study design, endpoints, and progress, as well as upcoming catalysts. \nWith the completion of a successful financing in June 2023, NeuroSense is in a strong financial position with a capital runway beyond the expected readout of topline data from the Phase 2b PARADIGM trial in Q4 2023.\nInvestors interested in attending the event are invited to register here or RSVP via email: [email protected].\nAbout NeuroSense\nNeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.\nFor additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.\nForward-Looking Statements\nThis press release contains \"forward-looking statements\" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forwar...